Stockscreener 앱 받기
3.59
6.02%
-0.23
시간 외 거래:
3.59
전일 마감가:
$3.82
열려 있는:
$3.8
하루 거래량:
637.23K
Relative Volume:
0.64
시가총액:
$210.35M
수익:
-
순이익/손실:
$-117.81M
주가수익비율:
-1.9096
EPS:
-1.88
순현금흐름:
$74.30M
1주 성능:
+3.16%
1개월 성능:
+6.21%
6개월 성능:
-57.11%
1년 성능:
-34.13%
1일 변동 폭
$3.58
$3.87
1주일 범위
$3.34
$3.87
52주 변동 폭
$2.95
$13.60
Omeros Corporation Stock (OMER) Company Profile
명칭
Omeros Corporation
전화
206-676-5000
주소
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
3.59 | 223.82M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-10 | 개시 | H.C. Wainwright | Buy |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-14 | 개시 | Rodman & Renshaw | Buy |
| 2022-12-08 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-11-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-06-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2021-10-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2021-10-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-09-27 | 개시 | JP Morgan | Neutral |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-08-21 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-14 | 재확인 | Maxim Group | Buy |
| 2019-05-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 개시 | Seaport Global Securities | Buy |
| 2018-03-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-03-05 | 다운그레이드 | Needham | Buy → Hold |
| 2017-11-08 | 개시 | H.C. Wainwright | Buy |
| 2017-05-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 재확인 | Maxim Group | Buy |
| 2017-03-17 | 재확인 | Needham | Buy |
| 2016-11-16 | 재확인 | Wedbush | Outperform |
| 2016-11-10 | 재확인 | Needham | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-06-03 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-02 | 재확인 | Needham | Buy |
| 2016-02-29 | 재확인 | Wedbush | Outperform |
| 2015-11-11 | 재확인 | Needham | Buy |
| 2015-08-18 | 재확인 | WBB Securities | Strong Buy |
| 2015-08-10 | 개시 | ROTH Capital | Buy |
모두보기
Omeros Corporation 주식(OMER)의 최신 뉴스
What analysts say about Omeros Corporation stockExceptional profit potential - Autocar Professional
Omeros Corporation Stock Analysis and ForecastPhenomenal trading returns - jammulinksnews.com
What drives Omeros Corporation stock priceStrongest growth potential - jammulinksnews.com
Why Omeros Corporation stock attracts strong analyst attentionAnalyst Grade Signals - Newser
Is Omeros Corporation a good long term investmentSky-high profits - PrintWeekIndia
How Omeros Corporation stock performs during market volatilityStrategic High Profit Opportunities - beatles.ru
what makes omeros corporation stock price move sharplyFree Access to Community - Newser
FY2027 Earnings Forecast for Omeros Issued By HC Wainwright - Defense World
What makes Omeros Corporation stock price move sharplyWatchlist Winner Update - Newser
Omeros Corporation (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Omeros gets FDA acceptance for narsoplimab BLA resubmission - MSN
Wealth Enhancement Advisory Services LLC Takes $579,000 Position in Omeros Corporation (NASDAQ:OMER) - Defense World
Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost - MSN
Both retail investors who control a good portion of Omeros Corporation (NASDAQ:OMER) along with institutions must be dismayed after last week's 12% decrease - simplywall.st
Omeros shareholders elect directors and approve executive pay at annual meeting - Investing.com
Omeros stock maintains Buy rating at H.C. Wainwright on EU submission - Investing.com
Omeros (NASDAQ:OMER) Downgraded by Wall Street Zen to “Sell” - Defense World
Omeros' Narsoplimab: A Lifeline for TA-TMA Patients and a Regulatory Crossroads - AInvest
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA | OMER Stock News - GuruFocus
Omeros (OMER) Eyes European Approval for Key Drug Narsoplimab | OMER Stock News - GuruFocus
Omeros Announces Webcast Details for Annual Meeting of Shareholders - FinancialContent
Ratios Revealed: Decoding Omeros Corporation (OMER)’s Financial Health - DWinneX
Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
What is HC Wainwright’s Forecast for Omeros FY2025 Earnings? - Defense World
HC Wainwright Predicts Omeros’ Q2 Earnings (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Now Covered by Analysts at HC Wainwright - Defense World
Cantor Fitzgerald Comments on Omeros FY2026 Earnings - Defense World
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga
Trend Tracker for (OMER) - news.stocktradersdaily.com
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OME - GuruFocus
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OMER Stock News - GuruFocus
HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target - MarketScreener
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval - GuruFocus
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval | OMER Stock News - GuruFocus
Omeros Corporation (OMER) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
1.57%
자본화:
|
볼륨(24시간):